
Objective

This document outlines current knowledge on the clinical significance of blood group alloantibodies. Its prime purpose is to enable clinical decisions to be made regarding the management and blood transfusion support of patients with blood group antibodies that are not commonly encountered and for which antigen-negative blood may not be available in the routine stock. The overall aim is to ensure that a uniform RCI Clinical Policy for the supply of blood for transfusion is implemented throughout NHSBT

Changes in this version

The antibody index provided toward the end of this document refers the reader to the relevant section according to the ISBT blood group system number classification e.g. anti-U, section 2 for MNS. These sections are found in pages 11 to 27.

Addition of information about antibodies to new antigens in existing systems.

Addition of newly established blood group systems.

Removal of obsolete antigen RHAG4.

Addition of process prompts when antigen negative blood is recommended for strong examples of an antibody throughout this document, to reflect a process change.

Update to contact information to reflect changes in the process of finding and requesting rare units when required.

General Requirements

Many of the antibodies described in this document are directed to high frequency antigens and may create difficulties in obtaining compatible blood. Red cells negative for high frequency antigens are not readily available and availability should be discussed with the National Frozen Blood Bank (NFBB). Finding compatible blood should create no difficulty for patients with antibodies to antigens of lower frequency, but these antibodies may have to be considered when multiple specificities are present. Antibodies to low frequency antigens may have the potential to cause haemolytic disease of the fetus and newborn (HDFN). Therefore, the clinical significance of many of these antibodies is also described in this document.

It is not possible to provide a strict policy on whether or not antigen-negative blood is required for transfusion, based purely on the specificity of the antibody. Other factors that need to be considered are:

13. how urgently blood is required;
14. the clinical diagnosis and the patient's bone marrow function;
15. whether the patient is immunologically compromised and unlikely to respond;
16. strength and thermal amplitude of the antibody;
17. class and subclass of the immunoglobulin;
18. results of *in vitro* functional assays (e.g. a monocyte chemiluminescence assay, which may provide some indication of the potential clinical significance of the antibody);
19. *in vivo* red cell survival. (Studies are difficult to correlate with clinical outcome as the behaviour of a small volume of labelled red cells may not accurately reflect the response to the transfusion of a large volume of red cells. Red cell survival studies are undertaken by very few service laboratories.)

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Where BSH guidelines are provided for an antibody specificity these should be followed¹.

When an antibody is identified and considered to be of no clinical significance, particular care must be taken to ensure that it is not masking the presence of another, clinically significant, antibody.

Requests for rare units

When rare units are required, all new cases should be authorised by the RCI/on-call consultant who should establish the clinical need, urgency and number of units required and inform the centre RCI BMS. [The RCI BMS should , carry out the search \(NFBB staff are available in hours, to aid with wet and frozen searches, if necessary\).](#) Search the NHSBT PULSE database to see if wet units are available, or if the possibility of rare donor call up is viable before deciding to use frozen red cells. Where suitable units are not available in the NFBB, IBGRL should be contacted for advice regarding availability of donors on the IRDP.

National Frozen Blood Bank -	(5) 7165	[Out of hours – (5)7170] frozen.bank@nhsbt.nhs.uk
IBGRL (Red Cell Reference)-	(2) 7587	rare.donor@nhsbt.nhs.uk

When compatible blood is not readily available – see INF437

When antigen-positive blood is to be transfused – see INF437

It is important to note that antibodies that show strong reactivity by IAT may be more active *in vivo* than if the same antibody showed weaker reactions. Where possible ‘serologically least incompatible’ units should be selected. Some of the antibodies listed are extremely rare and little or nothing is known about their clinical significance^{2,3,4}. Absence of evidence of clinical significance does not mean that a transfusion of ‘incompatible’ blood will be uneventful.

For some antibodies the recommendation is that ‘serologically least incompatible’ red cells may be given, but that antigen-negative red cells should be provided for strong examples of the antibody (Table 1). Generally, a strong example of the antibody would be one giving a reaction strength grade 3 or greater (on a scale of 0-5) by IAT. Many antibodies to high frequency antigens will react the same strength with all antigen positive cells. In these cases, ‘serologically least incompatible’ may apply to all suitable units selected for cross match.

Where it states that ‘serologically least incompatible red cells should be used with extra caution’. Suggest close monitoring of pulse, blood pressure and temperature.

[Where antigen negative blood is recommended for strong examples of an antibody \(≥3+\) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.](#)

Antibodies to low frequency antigens

Either blood negative for the corresponding antigen or blood compatible by IAT at 37°C, as appropriate, may be supplied.

HDFN

Whenever an IAT-reactive antibody is detected during pregnancy, a cord sample should be tested by a DAT and, if positive, the haemoglobin and bilirubin levels monitored to diagnose HDFN. Haemolysis caused by antibodies to red cell antigens of low frequency is generally not sufficiently severe to require intra-uterine transfusion (IUT), but blood may be required for neonatal transfusion. It should be noted that frozen and thawed red cells are both safe and effective for intrauterine and exchange transfusions (coagulation tests should be undertaken during and after neonatal exchange transfusions; in rare cases where there is a risk of bleeding, fresh frozen plasma (FFP) transfusions may be required).

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Table 1. Recommendations for red cells to be selected for transfusion

Antibody	Recommendation
ABO	
Anti-A, -B, -A,B	Antigen-negative red cells
Anti-A ₁	Red cells compatible by IAT at 37°C
MNS	
Anti-M (active at 37°C), -S, -s	Antigen-negative red cells
Anti-U made by S-s-U- individuals	Antigen-negative red cells
Anti-U made by S-s-U ^{var} individuals	S-s-U ^{var} red cells, compatible by IAT at 37°C, but S-s-U- red cells if S-s-U ^{var} red cells are incompatible
Anti-N (active at 37°C), -En ^a and antibodies to low frequency MNS antigens	Red cells compatible by IAT at 37°C
P1PK	
Anti-P1 (active at 37°C)	Red cells compatible by IAT at 37°C
Anti-PP1P ^k	See GLOB section below
Rh	
All Rh antibodies (except those listed below)	Antigen-negative red cells
Anti-C ^w (including when previously detected but not detectable in current sample)	Red cells compatible by IAT at 37°C
Anti-hr ^S , -hr ^B and e-like antibodies made by individuals with variant e.	Ideally antigen negative (e-), however additional factors must be considered for blood selection in these cases. See INF1302 for product selection guidance.
Lutheran	
Anti-Lu ^a (including when previously detected but not detectable in current sample)	Red cells compatible by IAT at 37°C
Anti-Lu ^b , -Lu3	Antigen-negative red cells
Antibodies to other high frequency Lutheran antigens	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Antibody	Recommendation
Kell	
All Kell antibodies (except anti-Kp ^a , -UJ ^a , -K17, -Kp ^c , -K23, -	Antigen-negative red cells

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

K24, -VLAN, -VONG, -KYO and -KEAL)	
Anti-Kp ^a , U ^a , -K17, -Kp ^c , -K23, -K24, -VLAN, -VONG, -KYO, -KEAL (including when previously detected but not detectable in current sample)	Red cells compatible by IAT at 37°C
Lewis	
Anti-Le ^a , -Le ^b , -Le ^{ab}	Red cells compatible by IAT at 37°C
Duffy	
All Duffy antibodies	Antigen-negative red cells
Kidd	
All Kidd antibodies	Antigen-negative red cells
Diego	
Anti-Di ^b	Antigen-negative red cells
Anti-Wr ^b	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Anti-DISK	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Anti-Di ^a	Red cells compatible by IAT at 37°C
Anti-Wr ^a (including when previously detected but not detectable in current sample)	Red cells compatible by IAT at 37°C
Other Diego antibodies (all to low frequency antigens)	Red cells compatible by IAT at 37°C
Yt	
Anti-Yt ^a	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Anti-YTEG, -YTLI, -YTOT, -YTGT	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Antibody	Recommendation
Anti-Yt ^b	Red cells compatible by IAT at 37°C
Xg	
Anti-Xg ^a	Red cells compatible by IAT at 37°C
Anti-CD99	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution

Controlled if copy number stated on document and issued by QA

(Template Version 03/02/2020)

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Scianna	
Anti-Sc1	Antigen-negative red cells
Anti-Sc2, -Rd	Red cells compatible by IAT at 37°C
Anti-Sc3, -STAR, -SCER, -SCAN, -SCAR, -SCAC	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Dombrock	
Anti-Do ^a , -Do ^b	Ideally antigen-negative red cells, but if typed donors are not available, red cells compatible by IAT at 37°C should be selected
Anti-Gy ^a , -Hy, -Jo ^a and other Dombrock antibodies	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Colton	
Anti-Co ^a	Antigen-negative red cells
Anti-Co ^b	Red cells compatible by IAT at 37°C
Anti-Co3, -Co4	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Landsteiner-Wiener	
Anti-LW ^a , -LW ^{ab}	Serologically least incompatible D– red cells
Anti-LW ^b	Red cells compatible by IAT at 37°C
Chido/Rodgers	
Chido/Rodgers antibodies	Serologically least incompatible red cells
H	
Anti-H (in O _h individuals)	Antigen-negative red cells
Anti-H/Hi (in para-Bombay secretors)	Red cells compatible by IAT at 37°C (use ABO-identical)
Anti-Hi (in patients with common ABO phenotypes)	Red cells compatible by IAT at 37°C
Antibody	Recommendation
Kx	
Anti-Kx	Antigen-negative red cells
Gerbich	
Gerbich antibodies	Serologically least incompatible red cells
Cromer	
Cromer antibodies	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Knops	
Knops antibodies	Serologically least incompatible red cells
Indian	
Anti-In ^a	Red cells compatible by IAT at 37°C
Anti-In ^b	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Anti-INFI, -INJA, -INSL	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Ok	
Anti-Ok ^a , -OKGV, -OKVM	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Raph	
Anti-MER2	Serologically least incompatible red cells
John Milton Hagen	
Anti-JMH	Serologically least incompatible red cells
I	
Alloanti-I (active at 37°C)	Antigen-negative red cells
Autoanti-I	Red cells compatible by IAT at 37°C
Globoside	
Anti-P, -PP1P ^k	Antigen-negative red cells
Anti-PX2 (anti-P is always present with this antibody)	Ideally antigen-negative (P ^k phenotype) red cells, but if not available, p phenotype red cells must be used
Antibody	Recommendation
Gill	
Anti-GIL	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Rh-associated glycoprotein	
Anti-Duclos, -DSLK	Antigen-negative red cells
Anti-OI ^a , -Kg	Red cells compatible by IAT at 37°C
FORS	
Anti-FORS1	See blood group system 031 section

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

JR	
Anti-Jr ^a	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
LAN	
Anti-Lan	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Vel	
Anti-Vel	Antigen-negative red cells
CD59	
Anti-CD59	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Augustine	
Anti-At ^a	Serologically least incompatible red cells, but antigen-negative red cells for strong examples of the antibody
Anti-AUG1, -ATAM	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Anti-ATML	Red cells compatible by IAT at 37°C
Kanno	
Anti-KANNO1	Serologically least incompatible red cells
SID	
Anti-Sd ^a	Serologically least incompatible red cells [avoid Sd(a++) donors]
Antibody	Recommendation
CTL2	
Anti-VER, -RIF	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
PEL	
Anti-PEL	Serologically least incompatible red cells
MAM	
Anti-MAM	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
EMM	
Anti-Emm	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

ABCC1	
Anti-WLF	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
Cost collection	
Cost antibodies	Serologically least incompatible red cells
Er collection	
Anti-Er ^a	Serologically least incompatible red cells
Anti-Er ^b	Red cells compatible by IAT at 37°C
Anti-Er ³	Ideally antigen-negative red cells, but, due to their extreme rarity, serologically least incompatible red cells should be used with extra caution
High frequency (901)	
Anti-AnWj	Antigen-negative red cells
Anti-ABTI	Serologically least incompatible red cells
Anti-LKE	Serologically least incompatible red cells

Blood group antibodies

Antibodies are presented below in the order of the ISBT blood group classification. A table summarising the recommendations for selection of suitable blood is provided above (Table 1). The antibody index provided toward the end of this document refers the reader to the relevant section according to the ISBT blood group system number classification e.g. anti-U, section 002 for MNS.

001 ABO system

Anti-A, -B, and -A,B cause severe intravascular HTRs. **Antigen-negative blood must be selected for transfusion.**

Anti-A₁ is rarely active at 37°C and not considered clinically significant. **IAT-compatible blood should be selected (BSH guidelines).**

Plasma products with high titre ABO antibodies should only be given to group O recipients.

002 MNS system

Anti-M and -N can usually be ignored and are not detected by IAT at 37°C. Rarely anti-M or -N are active at 37°C and then are capable of causing transfusion reactions.

If anti-M is active by IAT at 37°C, M– blood must be selected (BSH guidelines).

If anti-N is active by IAT at 37°C, IAT-compatible blood unselected for N may be used.

About 22% of donors are M–

About 28% of donors are N–

Rarely, anti-M may cause HDFN.

Anti-S and -s can cause HTRs. **Antigen-negative blood must be selected (BSH guidelines).**

About 45% of donors are S–

About 11% of donors are s–

Anti-S and -s may cause HDFN.

Anti-U detects a high frequency antigen and has caused immediate and delayed HTRs. S–s–U– and S–s–U+^{var} individuals can make anti-U. **S–s–U– blood must be selected for S–s–U– individuals with anti-U. To conserve S–s–U– blood stocks, IAT-compatible S–s–U+^{var} red cells should be considered for S–s–U+^{var} individuals with anti-U.**

Occasionally **anti-N present in rare N– S–s–U– patients**, reacts by IAT at 37°C with all red cells except those of the N– S–s–U– phenotype. **When this occurs, N– S–s–U– blood should be selected.**

S–s–U– and S–s–U+^{var} blood is usually only found in people of African origin. Contact NFBB for information regarding availability of ‘wet’ and frozen S–s–U– and S–s–U+^{var} units.

Anti-U may cause HDFN.

Other antibodies to high frequency MNS antigens. These are the En^a family of antibodies and are exceedingly rare alloantibodies. There are single reports of **anti-En^a** causing a severe HTR and severe HDFN. **If possible IAT-compatible blood should be selected.** Consult IBGRL for availability of En(a-) donors on the IRDP.

Antibodies to low frequency MNS antigens. Antibodies generally referred to as anti-Mi^a (including anti-Mur and -Vw) and the antigens they define are rare in England but relatively common in people from East Asia. They can cause immediate and delayed HTRs and severe HDFN. **IAT-compatible blood (most donors) must be selected.**

003 P1PK system

P1 antibodies are not usually reactive above 25°C and do not cause HTRs. Very rare examples of anti-P1 are reactive at 37°C and can cause severe immediate or delayed HTRs. **Units compatible by IAT (using polyspecific anti-human globulin reagent at 37°C) should be used for transfusion when anti-P1 active at 37°C is present.**

About 20% of donors are P1-.

Anti-P1 has not been implicated in HDFN.

004 Rh system

All Rh antibodies should be considered to be potentially clinically significant, capable of causing both HTRs and HDFN. **BSH guidelines recommend that when an Rh antibody reactive by IAT (the majority of Rh antibodies) is present, antigen-negative blood must be selected. The exceptions are anti-C^w (see below) and e-like antibodies (anti-hr^s, -hr^b), detected in patients with variant e (see section below).**

All Rh antibodies have the potential to cause HDFN.

Antibodies to high frequency Rh antigens are rare. They include anti-Rh29, the antibody characteristically made by immunised Rh_{null} individuals, and anti-Rh17 (-Hr₀) and related antibodies that detect epitopes on the RhCcEe protein.

Anti-Rh29 Only Rh_{null} blood, which is extremely rare, is suitable.

Anti-Rh17 (-Hr₀). Only Rh_{null} or D-- blood is suitable.

Other antibodies to high frequency RhCcEe antigens. These include antibodies such as **anti-Hr, -Hr^b, -Rh46, and -MAR.** Rh_{null} or D-- blood would be suitable, but it may be easier to obtain blood lacking the specific antigen.

e-like antibodies. Anti-hr^s and -hr^b resemble anti-e and may be found in patients of African origin with variant e. They have not been reported to be clinically significant, but a particularly potent example might cause problems. R₂R₂ cells should be compatible, but the patient may then be stimulated to produce **anti-E, if the patient is E-, or anti-D if the patient is D- or D+^{var}.** **See INF1302 for product selection guidance.**

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-C^W is a relatively common antibody. There is no report of anti-C^W causing a transfusion reaction and IAT-compatible blood may be selected. Anti-C^W has been implicated in HDFN, one case of hydrops fetalis, attributed to anti-C^W, has been reported.

About 97% of donors are C^W-.

Antibodies to low frequency antigens. The Rh system contains many low frequency antigens. Antibodies to these antigens should all be considered to have the potential to cause HDFN. Anti-E^w, -Go^a, -Rh32, -Be^a, -Evans, and -Tar have all been implicated in HDFN.

005 Lutheran system

Anti-Lu^a has caused mild DHTRs. **IAT-compatible blood should be selected.**

About 92% of donors are Lu(a-).

Anti-Lu^b has caused mild DHTRs. **Antigen-negative blood should be selected.**

Anti-Lu3 is a very rare antibody produced by immunised individuals with the recessive type of Lu(a-b-) [Lu_{null} phenotype]. **Lu(a-b-) blood should be selected.** The dominant type of Lu(a-b-) [InLu phenotype] is most readily available.

Other antibodies to Lutheran system high frequency antigens have not been proven to be clinically significant. However, **as a precaution Lu(a-b-) blood should be selected for patients with strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody (≥3+) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

Lutheran antibodies have not been implicated in severe HDFN.

006 Kell system

Most Kell system antibodies are clinically significant and antigen-negative blood must be selected, except in the case of anti-Kp^a, in which only one case of severe DHTR is reported.

Kell antibodies have the potential to cause HDFN.

Anti-k has caused severe immediate HTRs. **k- blood must be selected.** K+k- blood has a frequency of about 0.2%. If blood is not available locally, contact NFBB.

Anti-Kp^b has caused delayed HTRs. **Kp(b-) blood must be selected.** Kp(a+b-) blood has a frequency of about 0.01%

Anti-Js^b has caused delayed HTRs. **Js(b-) blood must be selected.**

Anti-Ku, the antibody produced by immunised K₀ individuals, can cause severe HTR. **If possible, K₀ blood (very rare) should be selected.**

Other antibodies to high frequency Kell antigens. These are very rare antibodies. None is reported to have caused an HTR, but **antigen-negative blood is recommended if possible**. In most cases, the only antigen-negative blood available will be K₀ blood (see above).

Antibodies to high frequency Kell antigens have been implicated in HDFN.

Antibodies to low frequency Kell antigens:

Anti-Js^a: antigen-negative blood (most donors) must be selected.

Anti-Kp^a, -UI^a, -K17, -Kp^c, -K23, -K24, -VLAN, -VONG, -KYO, -KEAL: IAT-compatible blood is suitable.

Antibodies to low frequency Kell antigens have been implicated in HDFN.

007 Lewis system

Lewis antibodies not active at 37°C (most) are not clinically significant, and can be ignored when selecting blood for transfusion.

For anti-Le^a, -Le^b, and -Le^{ab}, blood compatible by IAT at 37°C should be selected (BSH guidelines).

Most anti-Le^b have Le^{bH} specificity and might react strongly with group O red cells, but be non-reactive with group A₁ or B cells.

About 80% of donors are Le(a-).

About 30% of donors are Le(b-).

Lewis antibodies have not been implicated in severe HDFN.

008 Duffy system

Anti-Fy^a and -Fy^b have caused immediate and delayed HTRs

The BSH guidelines recommend that when Duffy antibodies are present, antigen-negative blood must be selected.

Both have the potential to cause HDFN.

About 32% of donors are Fy(a-).

About 20% of donors are Fy(b-).

Anti-Fy3 is a rare antibody detecting antigens on all red cells except those of the Fy(a-b-) phenotype. Anti-Fy3 has caused immediate and delayed HTRs. **Fy(a-b-) blood must be selected.**

Anti-Fy5 is a rare antibody, similar to anti-Fy3, but it does not react with Fy(a-b-) or Rh_{null} cells. Anti-Fy5 has caused delayed HTRs; **Fy(a-b-) blood must be selected.**

Fy(a-b-) phenotype is rare in Caucasians, but very common in people of African origin.

Anti-Fy3 and -Fy5 have not been implicated in severe HDFN.

009 Kidd system

Anti-Jk^a and -Jk^b are dangerous antibodies as they are often difficult to detect, yet they are a common cause of delayed HTRs. Anti-Jk^a has also caused immediate HTRs.

The BSH guidelines recommend that when Kidd antibodies are present, antigen-negative blood must be selected.

About 24% of donors are Jk(a-).

About 27% of donors are Jk(b-).

Kidd antibodies do not usually cause HDFN, though there are reports of severe HDFN caused by anti-Jk^a and anti-Jk^b.

Anti-Jk3 is a very rare antibody that reacts with all red cells except those of the Jk(a-b-) phenotype. It can cause immediate and delayed HTRs. **Jk(a-b-) blood must be selected.**

Anti-Jk3 has not been implicated in HDFN.

010 Diego system

Anti-Di^a detects an antigen that is very rare in Caucasians, but polymorphic in people of Eastern Asia and Native Americans. There is no firm evidence that anti-Di^a has caused an HTR, but anti-Di^a has haemolytic potential. **IAT compatible blood (most donors) must be selected.**

Anti-Di^a has been implicated in severe HDFN.

Anti-Di^b is a rare antibody that detects an antigen of very high frequency. Anti-Di^b has been implicated in HTRs and HDFN. **Antigen-negative blood should be selected.**

Anti-Wr^a is a relatively common antibody to a very low frequency antigen. It has caused HTRs. **If anti-Wr^a is detected, IAT-compatible blood must be selected.**

Anti-Wr^a has caused severe HDFN

Anti-Wr^b is a rare alloantibody to a very high frequency antigen. There is no report of anti-Wr^b causing an HTR or HDFN but information is very limited. **If possible, antigen-negative blood should be selected.** Wr(b-) blood is extremely rare.

Anti-DISK is an extremely rare antibody. Only one example of anti-DISK is known and there is no information regarding clinical significance⁵. The example of anti-DISK was described as very strong, showing characteristics indicative of a potentially clinically significant antibody. **DISK- blood should be selected but is not likely to be available, then serologically least incompatible blood should be used with extra caution.**

Other antibodies of the Diego system all detect antigens of very low frequency. None has caused an HTR, but anti-ELO (-DI8) has caused severe HDFN. **IAT-compatible blood (most donors) should be selected.**

011 Yt system

Anti-Yt^a detects an antigen with a frequency of about 99.7%. Anti-Yt^a has rarely been responsible for a HTR. **Yt(a–) blood is not usually required for transfusion but is recommended for strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody ($\geq 3+$) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

There is no report of anti-Yt^a causing HDFN.

Anti-YTEG, -YTLI, -YTOT, are rare antibodies to antigens of very high frequency. There is no information on clinical significance with regard to transfusion^{18,19}. **Serologically least incompatible blood should be used with extra caution.**

Anti-YTGT is a rare antibody to an antigen of very high frequency. There is one case report of anti-YTGT being implicated in a HTR¹⁴. **YTGT– blood should be selected but is not likely to be available, then serologically least incompatible blood should be used with extra caution.**

Anti-YTEG, -YTLI, -YTOT, -YTGT have not been implicated in HDFN. Cord cells have weak expression of YT antigens.

Anti-Yt^b detects an antigen with a frequency of about 8%. There is no report of anti-Yt^b causing a HTR or HDFN. **IAT compatible blood should be selected.**

012 Xg system

Anti-Xg^a detects an antigen with a frequency of 66% in males and 89% in females. There is no report of a HTR due anti-Xg^a. Xg^a typed donor blood is not available, but **IAT-compatible blood should be selected.**

Anti-Xg^a has not been implicated in HDFN.

Anti-CD99 is a rare antibody to an antigen of very high frequency. There is no information on clinical significance with regard to transfusion⁶. **Serologically least incompatible blood should be used with extra caution.**

Anti-CD99 has not been implicated in HDFN⁶.

013 Scianna system

Anti-Sc1, -Sc3, -STAR, -SCER, -SCAN, -SCAR and -SCAC detect antigens of very high frequency^{20,21}. Apart from a DHTR caused by anti-SCAN, there is no report of these antibodies causing a HTR or HDFN. The antibodies are IgG and usually potent, but evidence of clinical significance is limited because of the rarity of the antibodies. **Antigen-negative blood should be selected, if possible.** SC:–1, 2, 3 blood may be available, but is extremely rare. SC:–1,–2,–3 donors are not available. **When anti-Sc3, -STAR, -SCER, -SCAN, -SCAR or -SCAC are present, serologically least incompatible blood may be given with extra caution.**

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-Sc2 and -Rd detect antigens of low frequency. Neither antibody has been reported to have caused an HTR **IAT-compatible blood (most donors) should be selected.**

Anti-Sc2 and -Rd have been implicated in HDFN^{15,16}.

014 Dombrock system

Anti-Do^a and -Do^b are generally found in sera containing multiple red cell antibodies. They have caused immediate and delayed HTRs. Finding compatible blood may be complicated by the presence of the other antibodies. In some instances typed donors may not be available. **Ideally antigen-negative blood should be selected, however if typed donors are not available, IAT-compatible blood should be selected.**

About 34% of donors are Do(a-).

About 18% of donors are Do(b-).

Anti-Gy^a, -Hy, -Jo^a and other Dombrock antibodies are rare antibodies that detect antigens of very high frequency. There is one report of anti-Hy causing an HTR, but, because of the rarity of the antibodies, evidence of clinical significance is limited. **Antigen-negative blood is not usually required for transfusion but is recommended for strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody (≥3+) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

No Dombrock antibody has caused HDFN.

015 Colton system

Anti-Co^a detects an antigen of high frequency and has caused delayed HTRs and severe HDFN. **Co(a-) blood should be selected.**

About 0.2% of donors are Co(a-).

Anti-Co^b is a rare antibody that detects an antigen with a frequency of about 8.5%. An acute HTR and a mild DHTR due to anti-Co^b have been reported. **IAT-compatible blood (90% of donors) should be selected.**

Anti-Co^b has not been implicated in serious HDFN.

Anti-Co3, -Co4 are rare antibodies detecting antigens of very high frequency. Anti-Co3 has caused a mild HTR and serious HDFN. *There is no information regarding the clinical significance of anti-Co4 due to the rarity.* **Ideally, Co(a-b-) blood should be selected for compatibility testing but is extremely rare. Serologically least incompatible blood may be given with extra caution.**

016 LW system

Anti-LW^a and -LW^{ab} detect antigens of very high frequency. There is no report of either antibody causing a HTR. **Antigen-negative blood may not be required for transfusion, but D- blood should be selected when possible.**

Anti-LW^b, which detects an antigen of low frequency, has not been reported to have caused a HTR. **IAT-compatible blood (most donors) should be selected.**

No LW antibody has been implicated in HDFN.

017 Chido/Rodgers system

Chido/Rodgers antibodies detect C4 antigens present in plasma that become attached to the red cell surface *in vivo*. No Chido/Rodgers antibody has caused an HTR and **antigen-negative blood is not required for transfusion.**

Chido/Rodgers antibodies have been implicated in severe anaphylactic reactions following infusion of plasma products and platelet concentrates containing plasma, though these events are exceptional³.

018 H system

Anti-H is always present in the serum of individuals with the O_h (Bombay) phenotype (red cell H-deficient, non-secretor). Like anti-A and -B, anti-H is likely to cause a severe immediate HTR. **Blood of the O_h (Bombay) phenotype must be selected.**

Some non-secretors of A or B genotype have very low levels of red cell H and have the 'para-Bombay' A_h or B_h phenotype. These individuals usually have anti-H in their serum, though this is rarely of high titre. Little information exists on the clinical significance of anti-H in A_h or B_h individuals. **Ideally O_h (Bombay) phenotype should be selected, but if not available red cells of the appropriate ABO group (A for A_h, B for B_h) may be used with extra caution.**

Anti-H may rarely cause severe HDFN.

Anti-HI is present in the serum of individuals with some para-Bombay phenotypes (red cell H-deficient, secretor). Anti-HI is unlikely to be active at 37°C. **ABO-identical blood, compatible at 37°C, can be used for transfusion.**

Anti-HI may be found in group A₁, A₁B, and B individuals and may be active at 37°C. **Blood that is compatible at 37°C can be used for transfusion. If the antibody is active at 37°C, blood of the ABO group of the patient should be used. Group O and A₂ blood should not be used.**

019 Kx system

Anti-Kx is a rare antibody found in the serum of immunised McLeod males, usually together with anti-Km. Anti-Kx + -Km (often called anti-KL) has caused severe HTRs. **If possible, antigen-negative (McLeod phenotype) blood should be selected.**

020 Gerbich system

Anti-Ge2, -Ge3, -Ge4, -GEPL, -GEAT, -GETI, -GECT and -GEAR detect antigens of very high frequency^{22,23}. There is no firm evidence that any of these antibodies has caused a HTR. **Antigen-negative blood is not usually required for transfusion but should be considered for strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody ($\geq 3+$) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

Anti-Ge2 has not been implicated in HDFN. Anti-Ge3 has caused severe HDFN⁷. There is no information on clinical significance with regard to HDFN for anti-Ge4, -GEPL, -GEAT, -GETI, -GECT and -GEAR.

Antibodies to low frequency Gerbich antigens. None of these antibodies has caused an HTR or HDFN.

021 Cromer system

Anti-Cr^a, -Tc^a, -Dr^a, -IFC, and other antibodies to high frequency Cromer antigens. There is no firm evidence that any of these rare antibodies has caused a HTR and the evidence from functional cellular assays is equivocal. **Antigen-negative blood is not usually required for transfusion, but should be considered for strong examples of the antibody.** Typed donors are not available in the UK.

Where antigen negative blood is recommended for strong examples of an antibody ($\geq 3+$) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

Antibodies to low frequency Cromer antigens. None of these antibodies has caused an HTR.

No Cromer antibody has been implicated in HDFN.

022 Knops system

Anti-Kn^a, -McC^a, -SI^a, -SI3, -Yk^a, -KCAM detect antigens of relatively high frequency.

Anti-Kn^b, -McC^b, -Vil detect antigens of relatively low frequency.

Anti-KDAS, -DACY, -YCAD detect polymorphic antigens^{24,25}.

All of these antibodies can be considered to be of no clinical significance and can be ignored when selecting blood for transfusion. Use of least-incompatible blood will reduce the hazard of other, clinically significant, antibodies being masked.

No Knops antibody has caused HDFN.

023 Indian system

Anti-In^a is a rare antibody that detects an antigen that is rare in populations of European origin, but with a frequency of about 3% in Indians and 10% in Arabs. Anti-In^a is not reported to be clinically significant. **IAT-compatible red cells should be selected for transfusion.**

Anti-In^b is a rare antibody that recognises an antigen of very high frequency. There is one reported case of anti-In^b causing a HTR. **In(b–) blood is not usually required for transfusion but should be considered for strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody (≥3+) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

Anti-INFI, -INJA, -INSL are rare antibodies that recognise antigens of very high frequency^{8,17}. There is no clinical data available. INFI– blood, INJA– blood and INSL– blood is extremely rare. **Serologically least incompatible blood should be used with extra caution.**

Anti-In^a, -In^b, -INJA, -INSL have not been implicated in HDFN. Anti-INFI was implicated in one case of mild HDFN⁸.

024 Ok system

Anti-Ok^a, -OKGV, -OKVM. There is almost no information on the clinical significance of Ok antibodies, but *in vivo* survival tests and cellular functional assays suggest that anti-Ok^a is clinically significant. **Ok(a–) blood is extremely rare. When Ok(a–) blood is not available, serologically least incompatible blood may be given with extra caution.**

Ok antibodies have not been implicated in HDFN.

025 Raph system

Anti-MER2, the only antibody of the Raph system, detects an antigen of very high frequency, although the red cells of about 8% of Caucasians are serologically MER2–. There is one report of an HTR caused by anti-MER2. **Serologically least incompatible blood may be used for transfusion.**

Anti-MER2 has not been implicated in HDFN.

026 JMH system

Anti-JMH detects an antigen of high frequency and JMH– is usually an acquired phenotype. Anti-JMH is not considered clinically significant. **Serologically least incompatible blood may be used for transfusion.**

Anti-JMH has not been implicated in HDFN.

027 I system

Anti-I is always present as an alloantibody in the serum of individuals with the rare adult i phenotype (I– i+), although it is more commonly found as an autoantibody in CHAD patients. I+ blood transfused to patients with allo anti-I has caused increased destruction of cells and therefore **I– blood should be considered if the anti-I is active at 37°C.**

Anti-I has not been implicated in HDFN.

028 Globoside system

Anti-P and anti-P,P1,P^k are antibodies always present in individuals with the rare P^k and p phenotypes, respectively. Both antibodies can react at 37°C, be strongly haemolytic, and can cause HTRs. **Antigen-negative red cells must be selected.** Both antibodies are compatible with p cells, anti-P is also compatible with P^k cells.

Neither anti-P nor anti-P,P1,P^k has been reported to cause HDFN, but there is a high rate of early spontaneous abortion.

Anti-PX2 detects an antigen of very high frequency, absent only from rare P^k cells. Anti-P is always present with anti-PX2 therefore there is no clinical information about anti-PX2 as a single specificity. Anti-PX2 may be detected in the plasma of P^k individuals in cross matching tests with p cells. The reactivity observed is usually very weak. When anti-PX2 is detected, **ideally antigen-negative blood should be selected, however due to the extreme rarity of P^k donors, if P^k red cells are not available, p red cells must be selected.**

029 Gill system

Anti-GIL is a rare antibody to an antigen of very high frequency. Anti-GIL may have been responsible for a HTR. **Serologically least incompatible blood should be used with extra caution.**

Anti-GIL has not been implicated in HDFN.

030 Rh-associated glycoprotein system

Anti-Duclos and –DSLK are rare antibodies to antigens of very high frequency. There is no information on clinical significance. **Antigen negative or Rh_{null} red cells should be selected.**

Anti-OI^a and -Kg detect very rare antigens and **IAT-compatible blood (most donors) should be selected.**

Anti-Kg has been implicated in severe HDFN²⁶. There is no information on clinical significance of anti-OI^a.

031 FORS

Anti-FORS1 detects an antigen of very low frequency. Most people have naturally occurring anti-FORS1 in their plasma. Very little is known about the clinical significance of anti-FORS1 in a transfusion setting, due to the extreme rarity of FORS1+ individuals (previously described as having the now obsolete A_{pae} phenotype).

032 JR system

Anti-Jr^a. There is little evidence that anti-Jr^a has caused a HTR (there is only one case report of DHTR⁹). **Jr(a–) blood is not usually required for transfusion, but should be considered for strong examples of the antibody.** Jr(a–) blood may not be available in the UK.

Where antigen negative blood is recommended for strong examples of an antibody (≥3+) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

Anti-Jr^a was implicated in two cases of fatal HDFN^{10,11}.

033 LAN system

Anti-Lan. One example of anti-Lan is reported to have caused an immediate HTR and **one example is reported to have caused a DHTR²⁷.** **Lan– blood is not usually required for transfusion but should be considered for strong examples of the antibody.**

Where antigen negative blood is recommended for strong examples of an antibody (≥3+) please contact an RCI consultant or patient facing consultant. This is to enquire how previous antigen positive transfusions have been tolerated and whether any previous transfusion reactions have been reported.

There is no report of anti-Lan causing serious HDFN.

034 Vel system

Anti-Vel are often complement-activating IgM antibodies that cause severe immediate HTRs. **Vel– blood must be selected.**

There is one case of anti-Vel implicated in causing severe HDFN¹².

035 CD59 system

Anti-CD59.1 is a rare antibody to an antigen of very high frequency. There is no information on clinical significance. **Serologically least incompatible blood should be used with extra caution.**

036 Augustine system

Anti-AUG1 is the antibody made by the only known AUG_{null} individual¹³. There is no clinical information available. There is no antigen-negative blood available, therefore **serologically least incompatible blood should be used with extra caution.**

Anti-At^a has been reported to have caused immediate and delayed transfusion reactions. **Ideally At(a–) blood should be selected but may not be available, therefore serologically least incompatible blood should be used with extra caution.** At(a–) blood may not be available in the UK.

Anti-ATAM recognises an antigen of very high frequency, there is no information regarding clinical significance of the antibody with regard to transfusion²⁸. There is no antigen-negative blood available, therefore **serologically least incompatible blood should be used with extra caution.**

There is only one report of anti-At^a implicated in causing mild HDFN, despite numerous cases of pregnant women with anti-At^a. There was no evidence of HDFN in the only case of anti-AUG1. There is no information regarding anti-ATAM with regard to HDFN.

Anti-ATML recognises an antigen of very low frequency, The only example of anti-ATML, was implicated as the cause of severe HDFN²⁹.

037 Kanno system

Anti-KANNO1 detects an antigen of very high frequency. To date the KANNO1– phenotype and anti-KANNO1 has only been found in Japanese individuals^{30,31}. Anti-KANNO1 is reported to not be clinically significant³⁰. **Serologically least incompatible blood should be used.**

Anti-KANNO1 has not been implicated in HDFN, despite numerous cases of pregnant women with anti-KANNO1.

038 SID system

Anti-Sd^a detects an antigen with a frequency of about 91%. The strength of Sd^a is very variable. Anti-Sd^a has been implicated as causing HTRs, following transfusion of Sd(a+++)
cells. Although anti-Sd^a is not generally considered a transfusion hazard, and Sd(a–) red cells are not required for transfusion **serologically least incompatible red cells should be selected [to avoid transfusion of Sd(a+++)
cells].**

Anti-Sd^a has not been implicated in HDFN.

039 CTL2 system (only abstract published)

Anti-VER and **anti-RIF** recognise antigens of very high frequency, there is no information regarding clinical significance of these antibodies³². There is no antigen-negative blood available, therefore **serologically least incompatible blood should be used with extra caution.**

040 PEL system

Anti-PEL is a rare antibody that recognises an antigen of very high frequency³³. *In vivo* survival studies suggest that anti-PEL would not cause a HTR. **Serologically least incompatible blood should be used.**

Anti-PEL has not been implicated in HDFN.

041 MAM system

Anti-MAM is a rare antibody that recognises an antigen of very high frequency³⁴. Results of the MMA suggest that anti-MAM has the potential to substantially reduce the survival of transfused MAM+ RBCs. **Ideally MAM– blood should be selected but is unlikely to be available**, therefore **serologically least incompatible blood should be used with extra caution.**

Anti-MAM has been implicated as the cause of **severe HDFN**.

042 EMM system

Anti-Emm recognises an antigen of very high frequency^{35,36}. Most cases of anti-Emm have been found in untransfused males and therefore thought to be naturally occurring. Only one case has been reported implicating anti-Emm in causing an acute HTR. **Ideally Emm– blood should be selected but is unlikely to be available**, therefore **serologically least incompatible blood should be used with extra caution.**

Anti-Emm has not been implicated in HDFN.

043 ABCC1 system (only abstract published)

Anti-WLF recognises an antigen of very high frequency, there is no information regarding clinical significance of the antibody³⁷. There is no antigen-negative blood available, therefore **serologically least incompatible blood should be used with extra caution.**

Blood Group Collections (200 series)

205 Cost collection

Anti-Cs^a detects an antigen of relatively high frequency.

Anti-Cs^b detects an antigen of relatively low frequency.

Both antibodies can be considered to be of no clinical significance and can be ignored when selecting blood for transfusion. Use of least-incompatible blood will reduce the hazard of other, clinically significant, antibodies being masked.

No Cost antibody has caused HDFN.

208 Er collection

Anti-Er^a is a very rare antibody. There is no evidence that anti-Er^a is clinically significant, however limited clinical data are available. Er(a–) blood is extremely rare. **Serologically least incompatible blood should be used with extra caution.**

Anti-Er^a has not been implicated in HDFN.

Anti-Er^b detects a low frequency antigen. Only two cases have been described. There is no information on clinical significance with regard to transfusion.

Anti-Er^b has not been implicated in HDFN.

Anti-Er³ is an extremely rare antibody. Only one case has been described (in a male, therefore no information on clinical significance regarding HDFN) where signs of mild haemolysis were observed following transfusion of one unit of incompatible red cells. There is no Er³– blood available, therefore **serologically least incompatible blood should be used with extra caution.**

Antibodies to antigens of low frequency (700 series)

Antibodies to low frequency antigens do not present a transfusion problem, as compatible blood is readily available.

Some of the antibodies in this series have caused HDFN: anti-JFV, -JONES, -HJK, and -REIT.

Antibodies to antigens of high frequency (901 series)

The antibodies in this section detect antigens of very high frequency.

Anti-AnWj has caused severe HTRs. **IAT-compatible blood must be selected.** Red cells of the Lu_{null} (dominant In(Lu) type) phenotype have very low expression of AnWj and are suitable for transfusion.

There is no report of anti-AnWj causing HDFN.

Anti-ABTI. Only three examples of anti-ABTI are known and there is little information on their clinical significance. ABTI– blood is not available. **Vel– red blood cells express ABTI weakly and therefore should be selected for crossmatch. Serologically least incompatible blood should be used.**

Anti-ABTI has not been implicated in HDFN.

Anti-LKE detect an antigen of high frequency absent from P^k and p cells. These antibodies are generally only active at low temperature and there is no report of a HTR. **Serologically least incompatible blood may be used.**

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Table 2 Antibodies to blood group antigens showing published clinical significance

Ag freq = Frequency of antigen detected. H = high. L = low. P = polymorphic.
HTR = haemolytic transfusion reaction. I = immediate. D = delayed.

Anti-		Ag freq	HTR	HDFN
ABO1	A	P	Yes. I	Possibly mild
ABO2	B	P	Yes. I	Possibly mild
ABO3	A,B	P	Yes. I	Usually mild
ABO4	A1	P	Yes. I & D if active at 37 C	No report
MNS1	M	P	Yes. I & D if active at 37 C	Severe
MNS2	N	P	Yes. I & D if active at 37 C	Possibly mild (1 case)
MNS3	S	P	Yes	Severe
MNS4	s	P	Yes. D	Severe
MNS5	U	P	Yes. I & D	Severe
MNS6	He	P	No report	No report
MNS7	Mi ^a	L	Yes. I & D	Severe
MNS9	Vw	L	Possibly	Severe
MNS10	Mur	P	Yes. I & D	Severe
MNS11	M ^g	L	No report	No report
MNS12	Vr	L	No report	No report
MNS13	M ^e	P	No report	No report
MNS14	Mt ^a	L	No report	Yes
MNS15	St ^a	L	No report	No report
MNS16	Rj ^a	L	No report	No report
MNS17	Cl ^a	L	No report	No report
MNS18	Ny ^a	L	No report	No report
MNS19	Hut	L	No report	No report
MNS20	Hil	L	No report	Yes (1 case)
MNS21	M ^v	L	No report	Yes
MNS22	Far	L	Yes (1 case)	Severe
MNS23	s ^D	L	No report	Yes
MNS24	Mit	L	No report	No report
MNS25	Dantu	L	No report	No report
MNS26	Hop	L	No report	No report
MNS27	Nob	L	Minor symptoms (1 case)	No report
MNS28	En ^a	H	Severe (1 case)	Severe (1 case)
MNS29	ENKT	H	No report	No report
MNS31	Or	L	No report	No report
MNS32	DANE	L	No report	No report
MNS33	TSEN	L	No report	No report
MNS34	MINY	L	No report	No report
MNS35	MUT	L	No report	No report
MNS36	SAT	L	No report	No report
MNS37	ERIK	L	No report	No report
MNS38	Os ^a	L	No report	No report
MNS39	ENEP	H	No report	No report
MNS40	ENEH	H	No report	No report
MNS41	HAG	L	No report	No report
MNS42	ENAV	H	No report	No report
MNS43	MARS	L	No report	No report
MNS44	ENDA	H	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
MNS45	ENEV	H	Yes. D (1 case)	No report
MNS46	MNTD	L	No report	No report
MNS47	SARA	L	No report	Yes
MNS48	KIPP	L	No report	No report
MNS49	JENU	H	No report	No report
MNS50	SUMI	L	No report	No report
P1PK1	P1	P	Yes. I & D if active at 37 C	No report
P1PK3	P ^k	L	No report	No report
P1PK4	NOR	L	No report	No report
RH1	D	P	Severe	Severe
RH2	C	P	Yes. I & D	Yes
RH3	E	P	Yes. I & D	Yes
RH4	c	P	Severe	Severe
RH5	e	P	Yes. I & D	Yes
RH6	f	P	Yes. D	Yes
RH7	Ce	P	Yes	Yes
RH8	C ^w	P	No report	Yes
RH9	C ^x	L	No report	Yes, mild
RH10	V	P	No report	No report
RH11	E ^w	L	No report	Yes
RH12	G	P	Yes	Yes
RH17	Hr ₀	H	No report	Severe
RH18	Hr	H	Severe	Severe
RH19	hr ^s	P	No report	No report
RH20	VS	P	No report	No report
RH22	CE	P	No report	No report
RH23	D ^w	L	No report	No report
RH27	cE	P	No report	No report
RH29	Rh29	H	Yes	Severe
RH30	Go ^a	L	Yes, D	Yes
RH31	hr ^B	P	No report	No report
RH32	Rh32	L	No report	Yes
RH33	Rh33	L	No report	No report
RH34	Hr ^B	H	No report	No report
RH35	Rh35	L	No report	No report
RH36	Be ^a	L	No report	Severe
RH37	Evans	L	No report	Yes
RH40	Tar	L	No report	Yes
RH42	Rh42	P	No report	Mild
RH44	Nou	H	No report	No report
RH45	Riv	L	No report	Mild
RH46	Sec	H	No report	Severe
RH47	Dav	H	No report	No report
RH48	JAL	L	No report	Mild
RH49	STEM	P	No report	Mild
RH50	FPTT	L	No report	No report
RH51	MAR	H	No report	Yes
RH52	BARC	L	No report	No report
RH53	JAHK	L	No report	No report
RH54	DAK	L	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
RH55	LOCR	L	No report	No report
RH56	CENR	L	No report	No report
RH57	CEST	H	No report	No report
RH58	CELO	H	No report	No report
RH59	CEAG	H	No report	No report
RH60	PARG	L	No report	No report
RH61	CEVF	H	No report	No report
RH62	CEWA	H	No report	No report
RH63	CETW	L	No report	Yes (1 case)
LU1	Lu ^a	P	Mild, D	No report
LU2	Lu ^b	H	Mild, D	No report
LU3	Lu3	H	No report	No report
LU4	Lu4	H	No report	No report
LU5	Lu5	H	No report	No report
LU6	Lu6	H	No report	No report
LU7	Lu7	H	No report	No report
LU8	Lu8	H	Yes. I	No report
LU9	Lu9	L	No report	No report
LU11	Lu11	H	No report	No report
LU12	Lu12	H	No report	No report
LU13	Lu13	H	No report	No report
LU14	Lu14	L	No report	No report
LU16	Lu16	H	No report	No report
LU17	Lu17	H	No report	No report
LU18	Au ^a	P	No report	No report
LU19	Au ^b	P	No report	No report
LU20	Lu20	H	No report	No report
LU21	Lu21	H	No report	No report
LU22	LURC	H	No report	No report
LU23	LUIT	H	No report	No report
LU24	LUGA	H	No report	No report
LU25	LUAC	H	No report	No report
LU26	LUBI	H	No report	No report
LU27	LUYA	H	No report	No report
LU28	LUNU	H	No report	No report
LU29	LURA	H	No report	No report
KEL1	K	P	Severe	Severe
KEL2	k	H	Severe	Severe
KEL3	Kp ^a	P	Yes. D. Severe in one case	Yes, severe in two cases
KEL4	Kp ^b	H	Yes, D	Yes, severe in two cases
KEL5	Ku	H	Severe	Yes (1 case)
KEL6	Js ^a	P	Yes, D	Yes, severe in one case
KEL7	Js ^b	H	Yes, D	Severe
KEL10	Uj ^a	L	No report	Yes (1 case)
KEL11	K11	H	No report	Possibly
KEL12	K12	H	No report	No report
KEL13	K13	H	No report	No report
KEL14	K14	H	No report	No report
KEL17	K17	L	No report	No report
KEL18	K18	H	No report	Yes, mild (1 case)
KEL19	K19	H	No report	No report
KEL20	Km	H	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
KEL21	Kp ^c	L	No report	No report
KEL22	K22	H	No report	Severe (1 case)
KEL23	K23	L	No report	No report
KEL24	K24	L	No report	No report
KEL25	VLAN	L	No report	No report
KEL26	TOU	H	No report	No report
KEL27	RAZ	H	No report	No report
KEL28	VONG	L	No report	Yes (2 cases)
KEL29	KALT	H	No report	No report
KEL30	KTIM	H	No report	No report
KEL31	KYO	L	No report	No report
KEL32	KUCI	H	No report	No report
KEL33	KANT	H	No report	No report
KEL34	KASH	H	No report	No report
KEL35	KELP	H	No report	No report
KEL36	KETI	H	No report	No report
KEL37	KUHL	H	No report	No report
KEL38	KYOR	H	No report	No report
KEL39	KEAL	L	No report	Severe (1 case)
LE1	Le ^a	P	Rarely, only abs active at 37 C	No report
LE2	Le ^b	P	Rarely, only abs active at 37 C	No report
LE3	Le ^{ab}	P	No report	No report
LE4	Le ^{bH}	P	Rarely, only abs active at 37 C	No report
LE5	ALe ^b	P	No report	No report
LE6	BLe ^b	P	No report	No report
FY1	Fy ^a	P	Yes. I & D	Yes, occasionally severe
FY2	Fy ^b	P	Yes. I & D	Yes (1 case)
FY3	Fy3	P	Yes. I & D	No report
FY5	Fy5	P	Yes. D	No report
JK1	Jk ^a	P	Severe. I & D	Not usually. 1 case severe
JK2	Jk ^b	P	Yes. D	Not usually
JK3	Jk3	H	Severe. I & D	No report
DI1	Dj ^a	P	Possibly (1 case)	Severe
DI2	Dj ^b	H	Yes	Yes
DI3	Wr ^a	L	Yes	Severe
DI4	Wr ^b	H	No report	No report
DI5	Wd ^a	L	No report	No report
DI6	Rb ^a	L	No report	No report
DI7	WARR	L	No report	No report
DI8	ELO	L	No report	Severe
DI9	Wu	L	No report	No report
DI10	Bp ^a	L	No report	No report
DI11	Mo ^a	L	No report	No report
DI12	Hg ^a	L	No report	No report
DI13	Vg ^a	L	No report	No report
DI14	Sw ^a	L	No report	No report
DI15	BOW	L	No report	No report
DI16	NFLD	L	No report	No report
DI17	Jn ^a	L	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
DI18	KREP	L	No report	No report
DI19	Tr ^a	L	No report	No report
DI20	Fr ^a	L	No report	No report
DI21	SW1	L	No report	No report
DI22	DISK	H	No report	No report
DI23	DIST	L	No report	No report
YT1	Yt ^a	H	Yes, D rarely	No report
YT2	Yt ^b	P	No report	No report
YT3	YTEG	H	No report	No report
YT4	YTLI	H	No report	No report
YT5	YTOT	H	No report	No report
YT6	YTGT	H	Yes (1 case)	No report
XG1	Xg ^a	P	No report	No report
XG2	CD99	H	No report	No report
SC1	Sc1	H	No report	No report
SC2	Sc2	L	No report	Yes, 2 cases, 1 severe
SC3	Sc3	H	No report	No report
SC4	Rd	L	No report	Yes
SC5	STAR	H	No report	No report
SC6	SCER	H	No report	No report
SC7	SCAN	H	No report	No report
SC8	SCAR	H	No report	No report
SC9	SCAC	H	No report (MMA indicated clinically significant, 1 case)	No report
DO1	Do ^a	P	Yes. I & D	No report
DO2	Do ^b	P	Yes. I & D	No report
DO3	Gy ^a	H	No report	No report
DO4	Hy	H	Yes (1 case)	No report
DO5	Jo ^a	H	No report	No report
DO6	DOYA	H	No report	No report
DO7	DOMR	H	No report	No report
DO8	DOLG	H	No report	No report
DO9	DOLC	H	No report	No report
DO10	DODE	H	No report	No report
CO1	Co ^a	H	Yes. I & D	Severe
CO2	Co ^b	P	Yes. I & D (1 case each)	No report
CO3	Co3	H	Mild (1 case)	Severe
CO4	Co4	H	No report	No report
LW5	LW ^a	H	No report	No report
LW6	LW ^b	P	No report	No report
LW7	LW ^{ab}	H	No report	No report
CH/RG			No report	No report
H1	H	H	Yes	Severe
XK1	Kx	H	Severe	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
GE2	Ge2	H	No report	No report
GE3	Ge3	H	Possibly	Yes
GE4	Ge4	H	No report	No report
GE5	Webb	L	No report	No report
GE6	Ls ^a	L	No report	No report
GE7	An ^a	L	No report	No report
GE8	Dh ^a	L	No report	No report
GE9	GEIS	L	No report	No report
GE10	GEPL	H	No report	No report
GE11	GEAT	H	No report	No report
GE12	GETI	H	No report	No report
GE13	GECT	H	Possibly (D, 1 case)	No report
GE14	GEAR	H	No report	No report
CROM1	Cr ^a	H	Possibly	No report
CROM2	Tc ^a	H	Possibly	No report
CROM3	Tc ^b	P	No report	No report
CROM4	Tc ^c	L	No report	No report
CROM6	Es ^a	H	No report	No report
CROM7	IFC	H	No report	No report
CROM8	WES ^a	P	No report	No report
CROM9	WES ^b	H	No report	No report
CROM10	UMC	H	No report	No report
CROM11	GUTI	H	No report	No report
CROM12	SERF	H	No report	No report
CROM13	ZENA	H	No report	No report
CROM14	CROV	H	No report	No report
CROM15	CRAM	H	No report	No report
CROM16	CROZ	H	No report	No report
CROM17	CRUE	H	No report	No report
CROM18	CRAG	H	No report	No report
CROM19	CROK	H	No report	No report
CROM20	CORS	H	No report	No report
KN1	Kn ^a	P	No report	No report
KN2	Kn ^b	P	No report	No report
KN3	McC ^a	P	No report	No report
KN4	Sl ^a	P	No report	No report
KN5	Yk ^a	P	No report	No report
KN6	McC ^b	P	No report	No report
KN7	Vil	P	No report	No report
KN8	Sl3	P	No report	No report
KN9	KCAM	P	No report	No report
KN10	KDAS	P	No report	No report
KN11	DACY	P	No report	No report
KN12	YCAD	P	No report	No report
IN1	In ^a	L	No report	No report
IN2	In ^b	H	Yes, I (1 case)	No report
IN3	INFI	H	No report	Mild (1 case)
IN4	INJA	H	No report	No report
IN5	INRA	H	No report	No report
IN6	INSL	H	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-		Ag freq	HTR	HDFN
OK1	Ok ^a	H	No report	No report
OK2	OKGV	H	No report	No report
OK3	OKVM	H	No report	No report
RAPH1	MER2	H	No report	No report
JMH1	JMH	H	No report	No report
JMH2	JMHK	H	No report	No report
JMH3	JMHL	H	No report	No report
JMH4	JMHG	H	No report	No report
JMH5	JMHM	H	No report	No report
JMH6	JMHQ	H	No report	No report
JMH7	JHMN	H	No report	No report
JMH8	JMHA	H	No report	No report
I1	I	H	No report	No report
GLOB1	P	H	Severe. I	No report
GLOB4	PX2	H	No report	No report
GIL1	GIL	H	No report	No report
RHAG1	Duclos	H	No report	No report
RHAG2	Oj ^a	L	No report	No report
RHAG3	DSLK	H	No report	No report
RHAG5	Kg	L	No report	Yes (1 case)
JR1	Jr ^a	H	Yes. D (mild)	Severe
LAN1	Lan	H	Yes. I (1 case), D (1 case)	No report
VEL1	Vel	H	Severe. I	Not usually. 1 case
CD59.1	CD59.1	H	No report	No report
AUG1	AUG1	H	No report	No report
AUG2	At ^a	H	Yes, I & D	Mild (1 case)
AUG3	ATML	L	No report	Severe (1 case)
AUG4	ATAM	H	No report	No report
KANNO1	KANNO1	H	No report	No report
SID1	Sd ^a	H	Possibly	No report
CTL2.1	VER	H	No report	No report
CTL2.2	RIF	H	No report	No report
PEL1	PEL	H	No report	No report
MAM1	MAM	H	No report (MMA indicates may be clinically significant)	Severe

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Anti-EMM1	Emm	Ag freq	HTR	HDFN
ABCC1.1	WLF	H	No report	No report
COST1	Cs ^a	P	No report	No report
COST2	Cs ^b	P	No report	No report
ER1	Er ^a	H	No report	No report
ER2	Er ^b	L	No report	No report
ER3	Er3	H	Mild (1 case)	No report
700002	By	L	No report	No report
700003	Chr ^a	L	No report	No report
700005	Bi	L	No report	Possibly
700006	Bx ^a	L	No report	No report
700017	To ^a	L	No report	No report
700018	Pt ^a	L	No report	No report
700019	Re ^a	L	No report	No report
700021	Je ^a	L	No report	No report
700028	Li ^a	L	No report	No report
700039	Milne	L	No report	No report
700040	RASM	L	No report	No report
700044	JFV	L	No report	Yes (1 case)
700047	JONES	L	No report	Yes (1 case)
700049	HJK	L	No report	Severe (1 case)
700050	HOFM	L	No report	Mild (1 case)
700054	REIT	L	No report	Yes (1 case)
901009	AnWj	H	Severe	No report
901015	ABTI	H	No report	No report
901017	LKE	P	No report	No report

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Index	A	001
	A ₁	001
	A,B	001
	ABCC1	043
	ABO	001
	ABTI	901series
	AnWj	901 series
	At ^a	036
	ATAM	036
	ATML	036
	AUG1	036
	Augustine	036
	B	001
	Be ^a	004
	Chido/Rodgers	017
	Co ^a	015
	Co ^b	015
	Colton	015
	Co3	015
	Co4	015
	Cr ^a	021
	Cromer	021
	Cs ^a	205
	Cs ^b	205
	CTL2	039
	C ^w	004
	Dj ^a	010
	Dj ^b	010
	Diego	010
	Do ^a	014
	Do ^b	014
	Dombrock	014
	Dr ^a	021
	DSLK	010
	Duclos	030
	Duffy	008
	e-like	004
	ELO	010
	Emm	042
	EMM	042
	En ^a	002
	Er	208
	Er ^a	208
	Er ^b	208
	Er3	208
	Evans	004
	E ^w	004
	FORS1	031
	Fy ^a	008
	Fy ^b	008
	Fy3	008
	Fy5	008
	Gerbich	020
	Ge2	020
	Ge3	020
	Ge4	020

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

GEPL	020
GEAT	020
GETI	020
GIL	029
Gill	029
Globoside	028
Go ^a	004
Gy ^a	014
H	018
HJK	700
Hr	004
Hr ^B	004
hr ^B	004
hr ^S	004
Hr ₀	004
Hy	014
I	027
IFC	021
In ^a	023
In ^b	023
Indian	023
INFI	023
INJA	023
INSL	023
JFV	700
Jk ^a	009
Jk ^b	009
Jk3	009
JMH	026
Jo ^a	014
JONES	700
JR	032
Jr ^a	032
Js ^a	006
Js ^b	006
k	006
Kanno	037
KANNO1	037
KCAM	022
KEAL	006
Kell	006
Kg	030
Kidd	009
Kn ^a	022
Kn ^b	022
Knops	022
Kp ^a	006
Kp ^b	006
Kp ^c	006
Ku	006
Kx	019
KYO	006
K17	006
K23	006
K24	006
Lan	033

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

Le ^a	007
Le ^b	007
Le ^{ab}	007
Lewis	007
LKE	901
Lu ^a	005
Lu ^b	005
Lutheran	005
Lu3	005
LW	016
LW ^a	016
LW ^{ab}	016
LW ^b	016
M	002
MAM	041
MAR	004
McC ^a	022
McC ^b	022
MER2	025
Mj ^a	002
MNS	002
Mur	002
N	002
Ok	024
Ok ^a	024
OKGV	024
OKVM	024
Oj ^a	030
P	028
PEL	040
PP1P ^k	028
P1	003
P1PK	003
Raph	025
Rd	013
REIT	700
Rh	004
RhAG	030
Rh17	004
Rh29	004
Rh32	004
Rh46	004
RIF	039
S	002
s	002
Scianna	013
Sc1	013
Sc2	013
Sc3	013
SCAC	013
SCAN	013
SCAR	013
SCER	013
Sd ^a	038
SID	038
Si ^a	022

SPN214/5 – The Clinical Significance of Blood Group Alloantibodies and the Supply of Blood for Transfusion



Blood and Transplant

Copy No:

Effective date: 05/10/2022

SI3	022
STAR	013
Tar	004
Tc ^a	021
U	002
Uj ^a	006
Vel	034
VER	039
Vil	022
VLAN	006
VONG	006
Vw	004
Wr ^a	010
Wr ^b	010
WLF	043
Xg	012
Xg ^a	012
Yk ^a	022
Yt	011
Yt ^a	011
Yt ^b	011
YTEG	011
YTGT	011
YTLI	011
YTOT	011

References

1. Milkins C, Berryman J, Cantwell C, Elliott C, Haggas R, Jones J, Rowley M, Williams M, Win N. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. BSH guidelines. *Transfusion Medicine*, 23, 3-35 (2013).
2. Daniels G, Poole J, de Silva M, Callaghan T, MacLennan S, Smith N. The clinical significance of blood group antibodies. *Transfusion Medicine*, 12, 287-295 (2002).
3. Daniels G. *Human Blood Groups*. Blackwell Science, 3rd edition, 2013. ISBN 9781444333244.
4. Reid M, Lomas-Francis C, Olsson ML. *The Blood Group Antigen FactsBook (Third Edition)*, Academic Press, 2012. ISBN 9780124158498.
5. Poole J, Thornton NM, Tilley L, Lambert M, Fitzgerald J, Mulvanny L, Brassil M, Daniels G. Novel high incidence antigen in the Diego blood group system (DISK) and clinical significance of anti-DISK. *Vox Sang*, 99 (Suppl 1),30, (2010).
6. Thornton N, Karamatic Crew V, Muniz E, García- Arroba J, Nogués N, Lee E, Jones C, Schistal E, Jungbauer C, Allhoff W, Bullock T, Marais I, Daniels G. Four examples of anti-CD99 and discovery of the molecular bases of the rare CD99– phenotype. *Vox Sang*, 109 (Suppl. 1), 50 [Abstract] (2015).
7. Peterson D. Late onset neonatal anaemia due to anti-Ge: possible association with destruction of erythroid progenitors. *Transfusion Med*, 15, 125-132 (2005).
8. Poole, J., Tilley, L., Warke, N., Spring, F. A., Overbeeke, M. A.M., Van Der Mark-Zoet, J. A.C.M., Ahrens, N., Armstrong, D., Williams, M. and Daniels, G. Two missense mutations in the *CD44* gene encode two new antigens of the Indian blood group system. *Transfusion*, 47: 1306–1311. (2007).
9. Kwon M Y, Su L, Arndt PA, Garratty G, Blackall DP. Clinical significance of anti-Jr^a: report of two cases and review of the literature. *Transfusion*, 44, 197-201 (Feb 2004).
10. Peyrard T, Pham BN, Arnaud L, Fleutiaux S, Brossard Y, Guerin B, Desmoulins O, Rouger P, Le Pennec PY. Fatal hemolytic disease of the fetus and newborn associated with anti-Jr^a. *Transfusion*, 48, 1906-1911, (2008).
11. Aly M, AlKhrousi M, AlSheikh A, Juhail H, Varghese N, Al-Radwan R. Fatal Hemolytic Disease of the Fetus and Newborn Associated with Anti-Jra Alloimmunization. *Transfusion*, 58 (Suppl. 2), 187. [Abstract] (2018).
12. Le Masne A, Vachee A, Horbeyt C, Mannessier L, Gruca L, Rouland V, Lequien P. Forme severe de maladie hemolytique neonatale par allo-immunisation anti-Vel. *Arch Fr Pediatr*, 49, 899-901 (1992).
13. Daniels G, Ballif BA, Helias V, Saison C, Grimsley S, Mannessier L, Hustinx H, Lee E, Cartron J-P, Peyrard T, Arnaud L. Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization. *Blood*, 125 (23), 3651-3654, (2015).
14. Gillen, B., Lomas-Francis, C., Burgos, A., Imbryk, A., Dugger, J., Heibel, E., Lodermeier, M.A., Vege, S., Van Buren, N.L. and Westhoff, C.M., 2021, October. YTG^T: A New High-Prevalence Antigen in the Yt Blood Group System in Two Unrelated Native American Patients. In *2021 Virtual Annual Meeting*. AABB.
15. Lemay, A.S., Tong, T.N., Branch, D.R., Huang, M., Sumner, C., Oldfield, L., Hawes, J., Cserti-Gazdewich, C.M. and Lau, W., 2018. The first case of severe acute hemolytic transfusion reaction caused by anti-Sc2. *Transfusion*, 58(11), pp.2506-2512.
16. Rausen AR, Rosenfield RE, Alter AA, et al. A “new” infrequent red cell antigen, Rd (radin) *Transfusion*. 1967;7:336–42.
17. Henny, C., Thornton, N. and Lejon Crottet, S., 2018. An antibody against a novel high incidence antigen in the Indian blood group system. *Vox Sang*, 113(Suppl 1), p.231.
18. Baglow L, Laundry R, Karamatic Crew V, Eggington J, Asher O, Yahalom V, Folman C, Lighthart P, Veldhuisen B, Thornton N. Three new unrelated examples of the rare YTEG– phenotype and anti-YTEG. *Transf Med*. 2018; 28 (Suppl. 1): 40.

19. Karamatic Crew V, Laundry R, Walser P, et al. Serological and molecular characterisation of two novel high frequency antigens in the Yt blood group system. *Vox Sang.* 2018; 113 (Suppl 1):63.
20. Srivastava K, Albasri J, Alsuhaibani OM, et al. SCAR: The high-prevalence antigen 013.008 in the Scianna blood group system. *Transfusion.* 2021 Jan;61(1):246-254.
21. Hoffman R, Burgos A, Vail K, et al. A Decade-Long Search Finds a New High-Prevalence Antigen in the Sc System. *Transfusion.* 2021; 60(5):7A-260A.
22. Lomas-Francis C, Tahiri T, Vege S, et al. GECT: A New High-Prevalence Antigen in the GE Blood Group System in a SCD Patient with an Apparent Anti-GE2. *Transfusion.* 2020;60.
23. Shakarian G, Ong J, Vege S et al. A new antibody in the Gerbich blood system against a novel High prevalence antigen named GEAR. *Transfusion.* 2021;60.
24. Scharberg E, Schulz D, Stürtzel A, et al. A New Knops Antigen Antithetical to KCAM. *Transfusion* 2005;45 Suppl:27A
25. Grueger D, Zeretzke A, Habicht CP, et al. Two novel antithetical KN blood group antigens may contribute to more than a quarter of all KN antisera in Europe. *Transfusion.* 2020 Oct;60(10):2408-2418.
26. Tanaka M, Abe T, Minamitani T, et al. The Kg-antigen, RhAG with a Lys164Gln mutation, gives rise to haemolytic disease of the newborn. *Br J Haematol.* 2020 Dec;191(5):920-926.
27. Angelina A, Sapatnekar S, Bakdash S. Delayed Hemolytic Transfusion Reaction Due to Anti-Lan Antibody: A Case Report. *Transfusion.* 2017; 57 (Suppl. 3):139.
28. Vrignaud C, Mikdar M, Raneri A, Hermine O, Colin Y, Le Van Kim C, et al. Characterization of a novel high-prevalence red blood cell antigen in the Augustine blood group system (abstract). *Vox Sang.* 2018;113(Suppl 1):64–5.
29. Millard GM, McGowan EC, Wilson B, Martin JR, Spooner M, Morris S, et al. A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. *Transfusion.* 2018;58:1320–2.
30. Kawabata K, Uchikawa M, Ohto H, Yasuda H, Tsuneyama H, Tsuchida H, et al. Anti-KANNO: a novel alloantibody against a red cell antigen of high frequency. *Transfusion medicine reviews.* 2014; 28: 23-8.
31. Omae Y, Ito S, Takeuchi M, Isa K, Ogasawara K, Kawabata K, et al. Integrative genome analysis identified the KANNO blood group antigen as prion protein. *Transfusion.* 2019; 59: 2429-35.
32. Vrignaud C, Mikdar M, Koehl B, Nair TS, Yang L, Laiguillon G, et al. Alloantibodies directed to the SLC44A2 CTL2 transporter define two new red cell antigens and a novel human blood group system. *Transfusion.* 2019; 59:18A (Abstract).
33. Azouzi S, Mikdar M, Hermand P, et al. Lack of the multidrug transporter MRP4/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation. *Blood.* 2020;135(6):441-448. doi:10.1182/blood.2019002320
34. Thornton, N., Karamatic Crew, V., Tilley, L. et al. Disruption of the tumour-associated EMP3 enhances erythroid proliferation and causes the MAM-negative phenotype. *Nat Commun* 11, 3569 (2020). <https://doi.org/10.1038/s41467-020-17060-4>
35. Duval R, Nicolas G, Willemetz A, et al. Inherited glycosylphosphatidylinositol defects cause the rare Emm-negative blood phenotype and developmental disorders. *Blood.* 2021 Jul 1;137(26):3660-3669. doi: 10.1182/blood.2020009810 . PMID: 33763700.
36. Lane, W.J., Aeschlimann, J., Vege, S. et al. PIGG defines the Emm blood group system. *Sci Rep* 11, 18545 (2021). <https://doi.org/10.1038/s41598-021-98090-w>.
37. Sugier H, Vrignaud C, Duval R, Le Van Kim C, Arnoni C, Vendrame T, et al. Null Allele of ABCC1 Encoding the Multidrug Resistance Protein 1 Defines a Novel Human Blood Group System. *Vox sanguinis.* 2020;115(suppl 1):40-1(abstract).

Definitions

- **BSH** - British Committee for Standards in Haematology
- **DHTR** - Delayed Haemolytic Transfusion Reaction
- **HDFN** - Haemolytic Disease of the Fetus and Newborn
- **HTR** - Haemolytic Transfusion Reaction
- **IAT** - Indirect Antiglobulin Test
- **IBGRL** - International Blood Group Reference Laboratory
- **IRDP** - International Rare Donor Panel
- **NHSBT** - NHS Blood and Transplant
- **NFBB** - National Frozen Blood Bank
- **RCI** - Red Cell Immunohaematology

Related Documents / References

- ESD121: Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. BSH guidelines (Transfusion Medicine, 2013, 23, 3-35)
- INF437: Guidelines for the management of urgent red cell transfusion and situations when serological compatibility cannot be assured
- INF1302: HGP project – targets, phenotype prediction and product selection
- MPD1054: The provision of blood for patients with rare blood groups and/or multiple antibodies